What Your Pilot Needs to Show Before a Buyer Will Sign

A good healthcare pilot can stall when the finance lead asks for a number nobody recorded, or when the return lands on someone else’s budget.

Suppose a clinic pilots software that cuts documentation-related claim denials. The company reports that the denial rate fell from 30% to 5%. The clinic’s chief financial officer asks, “How much more cash did we collect? We already win back some of those denials on appeal.”

The pilot tracked denials. Nobody tracked what the clinic collected.

A missing number is one cause of a stalled sale among several. A pilot can also stall because there is no purchasing path. This post covers two causes that sit in the pilot’s own design: the number was never recorded, or the return belongs to someone other than the buyer. It applies to products a buyer purchases for a financial return, such as software, devices, diagnostics and some therapies.

What the CFO needed

A prevented denial can mean added revenue, earlier payment, or fewer hours spent on appeals. Each needs its own measure: dollars collected, days to payment, and staff hours logged on appeals.

Dollars collected and days to payment often sit in the clinic’s billing records, so a company can sometimes pull them afterward if the clinic agrees. Staff hours spent on appeals are different. Unless someone logged them during the pilot, the company can only estimate them, for example with a time study the clinic accepts, or run the pilot again.

The CFO’s next question will be “compared with what?” Seasonality, payer mix or a staffing change can move a denial rate without the product. Before the pilot starts, agree in writing on the comparison: the same clinic’s earlier months, or similar clinics without the software.

When the return belongs to someone else

I have worked with software startups whose return was real and well supported. They found out too late that the person paying for the software did not keep the return. The return landed upstream or downstream of the buyer: someone earlier or later in the chain of who pays, who uses and who benefits got a benefit that someone else paid for. The evidence was true, and it still held back adoption, because the person asked to sign gained nothing from it.

A device pilot shows the pattern. Suppose a device saves ten minutes per procedure, and the hospital committee that approves purchases asks whether those minutes become less overtime or one more case a day. Suppose also that the saving lands in the operating room’s budget while the purchase comes from the supply chain budget. Supply chain sees a higher price and no return, yet the hospital, which owns both budgets, may save money overall. Before the pilot starts, find out who can approve the purchase on the strength of the hospital-wide return and what evidence that person needs.

A drugmaker can face the same split. Suppose a therapy costs more than current care but could prevent hospital admissions. If the payer manages the pharmacy and medical benefits separately, the team that pays for the drug does not keep the savings from fewer admissions.

Three readers, one evidence plan

Two more people judge the same pilot with different questions.

What the investor needs

An investor asks, “After implementation and support, what margin can the company earn at the next ten clinics?” Implementation hours and support cost logged at the first clinic are the best estimate available. The investor’s question may take several deployments to answer, yet those hours have to be logged at the first clinic today.

What the acquirer needs

A strategic acquirer asks, “Which customers in our installed base would buy this, and what evidence supports that estimate?” I would expect an acquirer to start with the return the first buyer required, the return the pilot delivered, and how many customers in its own base operate under similar conditions. Contract terms are a second point: change-of-control, assignment and termination terms and data rights decide which customers an acquirer inherits.

The evidence plan

An integrated evidence generation plan, or evidence plan, is a written list of the facts the customer, the investor and a potential acquirer each need, the decision each fact informs, and who will collect it, how and by when. The sources differ: cash collected comes from billing records, implementation effort from time logs, and transfer rights from contracts. Some of those facts can only be logged while the pilot runs.

What outside sources show, and what they do not

In a 2020 STAT op-ed, two MedTech Innovator executives, Paul Grand and Kathryn Zavala, advised startups to ask the customer which metrics it will use to decide whether to sign a contract, as a way to size the pilot effort. The same section warns against putting too much money and effort into pilots. Elsewhere they call it a common mistake to plan evidence only for the next milestone and note that many startups run out of funding before they convince customers to buy. These points are the authors’ experience, not a study.

Galen Growth counted 282 exits among digital health ventures worldwide from 2025 through June 2026, and 268 were acquisitions (95%). That figure covers digital health, not MedTech or pharma, and says nothing about what acquirers read. It shows the acquirer is the usual exit there, a reason to ask the acquirer’s question early. Planning evidence only to the next milestone and leaving the acquirer’s question for later are the two gaps I check for in the plans I work on. I have worked on more than 30.

What goes in the pilot and what comes later

1. Name who pays, who uses it and who keeps the return. Draw that chain. If the return lands with someone other than the person who signs, the pilot has to show the signer a return the signer keeps, or show the person who can approve on the whole return what that person needs. If no such person exists, sell to whoever keeps the return.

2. Ask the buyer what number it needs to approve a purchase. Then agree on how to measure it and what to compare it with, before the pilot starts. In the clinic example, the number is additional cash ultimately collected on comparable claims, measured against an agreed earlier period. That keeps the CFO’s distinction between collecting more money and collecting the same money sooner.

3. Log what the pilot can produce. Implementation hours and support cost per site help estimate the margin at the next ten clinics. Ask counsel to check change-of-control, assignment and termination terms and data rights in the pilot agreement, because they decide whether an acquirer inherits the customer.

4. Give every other fact an owner, a cost and a date. Renewals cannot be counted until customers have had time to renew. A plan with no owner, no budget and no date is a wish list. If a measure would not change any of the three readers’ decisions, leave it out of the pilot budget.

The Bottom Line

A pilot reports what the product did. The evidence plan decides which numbers the buyer, the investor and the acquirer will each find.

Before your next pilot, ask the buyer one question: “What number will you need to see to approve a purchase, and how will we measure it together?”

The three readers come from EdgeGap, my methodology for startups, which treats customer value, investor value and acquirer value as three journeys that run at the same time. If you are designing a pilot and want a second reader on your evidence plan, schedule a call or get in touch at jfjordan.com.

-->